-
Amy Abernethy of the FDA: 800 active INDs for cell and gene therapy.
#STATSummit That's just crazy huge. Wonder what the breakdown is for gene replacement for rare genetic diseases vs engineered immune cells in cancer. -
This morning, I had the chance to kick off the inaugural
@statnews Summit. What a great line up of biopharma researchers, policymakers and patient advocates to discuss advances in science and emerging challenges that we need to address to continue to push forward.#STATSummit pic.twitter.com/jZF98pYwqm
-
Active debate about drug prices among biotech execs here at
#STATsummit. “Unfortunately, I think the industry has earned” its bad reputation, says Bluebird Bio’s Nick Leschly. pic.twitter.com/DR6baETNC1
-
SPICY! -->
$BIIB top scientist nearly dares FDA not to approve Alzheimer’s drug https://www.statnews.com/2019/11/21/biogen-al-sandrock-alzheimers/ …#STATSummit -
Speechless to see in person the future of bionic limbs at
#statsummit - absolutely unbelievable that this kind of technology is a reality. Jim’s story- a future STAT documentary- is a must watch. pic.twitter.com/UMR60tTBY9
-
.
@peterbachmd with an eye opening (as always) argument on whether our drug pricing system is prioritizing the right things. “I'm thrilled that we now have a treatment for ROS1, but I'm really worried that people are dying of suicides and opioid overdoses.”#STATSummit pic.twitter.com/R9jnHm7l3t
-
Talking with Erich Wohlhieter of
@Amgen about the future of AI and health care. He spoke about Crystal Bone project that analyzed a huge amount of patient data and can now predict a bone break due to osteoporosis with patients, so can predict and prevent.#STATSummit pic.twitter.com/7XSaQmgj19
-
Had a great convo with
@matthewherper at#STATsummit about the great work we are doing@US_FDA, including actions we’re taking to advance the technology we use to fulfill our public health mission as part of our Technology Modernization Action Plan.pic.twitter.com/ILoJjE417c
Prikaži ovu nit -
@mattmight says scientific studies should be freely available to families searching for disease treatments.#STATSummit -
Julie Grant, partner at VC firm Canaan: “we really have to listen to orgs like Walgreens and CVS when they say that people with cancer dont buy the drug, if they pay more than $300.“ Says industry needs to be focusing on that target out of pocket cost.
#STATSummit -
Anthony Yanni, SVP & Global Head, Patient Centricity, spoke at today’s
#STATSummit about what it means to be patient centric. “Integration of the patient perspective must start much earlier in, and be incorporated throughout, the drug discovery, development & delivery process.” pic.twitter.com/id9GZhefTY
-
great to chat with Dr. Charles Sawyers, who helped lead the development of the cancer drugs Gleevec and Xtandi
#STATSummit https://twitter.com/statnews/status/1197588776073252864 …
-
Last panel of the
#STATSummit and it's a good one: Biogen's Al Sandrock on the resurrection of the once scuttled Alzheimer's drug aducanumab Background on the scrutinized decision: https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/ … https://www.statnews.com/2019/10/23/experts-parse-biogens-alzheimers-data-does-the-treatment-work-or-is-it-a-mirage/ … https://www.statnews.com/2019/10/23/7-burning-questions-biogen-alzheimers-drug/ …pic.twitter.com/WoWTNUIe88
Prikaži ovu nit -
Looking forward to speaking at
#STATSummit, will cover innovation incentives and that they work, maybe too well. The gains are not distributed across society even though the costs are. pic.twitter.com/fS1CbW4AVM
-
“Artificial intelligence can help disrupt the conversation of cells in a precise, targeted way while the important conversations continue to flow.” –
@VirginiaSavova, Principle Senior Scientist, on#AI in biomedicine at today’s#STATSummit. pic.twitter.com/Tmh0fO3JYn
-
Provocative conversation today led by
@adamfeuerstein with biotech CEOs. They stated that they believed that the negative reputation of some biopharma companies was earned — particularly because of some drug pricing decisions.#STATSummit https://www.statnews.com/2019/11/21/biotech-ceos-own-up-to-bad-reputation/ … pic.twitter.com/xT4xiUhP2j
-
Quite a quote here from Bluebird's Nick Leschly! #STATSummit Story: https://www.statnews.com/2019/11/21/biotech-ceos-own-up-to-bad-reputation/ … -
If FDA approves aducanumab, running a placebo-controlled study will be difficult, says
$BIIB's Al Sandrock in response to question from@matthewherper if Biogen should do second trial.#STATSummit -
Jim Wilson says it's "kind of embarrassing" that the gene therapy technique he discovered in 2003 is still the best thing we've got https://www.statnews.com/2019/11/21/gene-therapy-pioneer-says-the-field-is-behind-and-that-delivery-technology-is-embarrassing/ …
#statsummit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.